FRANKFURT, July 29 German drugmaker Bayer saw underlying core earnings increase by one third in the second quarter, helped by strong overseas currencies and a gain in prescriptions of new drugs such a stroke prevention pill Xarelto.
Second-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.90 billion euros ($3.21 billion), compared with market expectations of 2.68 billion euros, while quarterly revenue gained 18 percent to 12.09 billion, also beating the analyst consensus.
09:14 Airbus seeks new talks with European nations over A400M costs16
07:15 Telefonica to sell up to 40 percent of Telxius to KKR for 1.3 billion euros21
14:29 Unilever rejects $143 billion Kraft Heinz bid as without merit20
12:33 Kraft Heinz to pursue merger despite Unilever rejection19